Phase 1B/2A, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 as an adjunct to best available therapy alone for the treatment of adults with bacteremia due to Staphylococcus aureus.